BeninTuberculosis profile
Population  2014 11 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1 (0.72–1.4) 9.8 (6.8–13)
Mortality (HIV+TB only) 0.31 (0.24–0.4) 3 (2.2–3.8)
Prevalence  (includes HIV+TB) 9.5 (5–15) 89 (47–145)
Incidence  (includes HIV+TB) 6.5 (5.3–7.9) 61 (50–74)
Incidence (HIV+TB only) 1 (0.82–1.3) 9.7 (7.7–12)
         
Case detection, all forms (%) 60 (49–73)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.5 (0.1–2) 4.8 (2.1–9.3)
MDR-TB cases among notified pulmonary
TB cases
17 (3–68) 11 (5–21)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 079   135
Pulmonary, clinically diagnosed 313   0
Extrapulmonary 359   0
       
Total new and relapse 3 886    
Previously treated, excluding relapses 91    
Total cases notified 3 977    
Among 3 079 new cases:
60 (2%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 81 (3%) 185 (82%) 266
Laboratory-confirmed RR-/MDR-TB cases     25
Patients started on MDR-TB treatment ***     16
TB/HIV 2014 Number (%)
TB patients with known HIV status 3 828 (96)
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (89) 3 254
Previously treated cases registered in 2013 (90) 242
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (75) 8
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 2.3
% Funded domestically 19%
% Funded internationally 48%
% Unfunded 32%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-07 Data: www.who.int/tb/data